Mehrizi Tahereh Zadeh, Rezayat Seyed Mahdi, Ardestani Mehdi Shafiee, Shahmabadi Hasan Ebrahimi, Ramezani Amitis
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran,Iran.
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran,Iran.
Curr Drug Deliv. 2021;18(9):1234-1243. doi: 10.2174/1567201818666210316111941.
In the present review study, the published articles from 2010-2020 that evaluated the effect of chitosan nanocarrier on the efficacy of amphotericin B (AmB) in the treatment of leishmaniasis, have been considered. Leishmania is a parasitic tropical disease in the world and is treated with AmB as one of the main therapeutic agents. However, the clinical application of AmB is limited due to its toxicity and insolubility issues. Using nanoparticles and, in particular, chitosan, nanocarrier seems a promising approach to overcome these problems. Therefore, various doses of AmB have been loaded in chitosan nanoparticles in different studies and the results of these studies demonstrated that by increasing the drug loading efficiency and decreasing the toxicity, the potency of the nanoformulation to inhibit and to kill the parasite is increased. In this regard, the results of a study performed in 2018, demonstrated that chitosan nanoparticles with the higher dose of drug loading were the most effective formulation to inhibit and kill the parasite. Thus, chitosan nanocarrier can consider as an appropriate candidate in the future to inhibit and kill the Leishmania parasite without causing side effects.
在本综述研究中，已考虑了2010年至2020年发表的评估壳聚糖纳米载体对两性霉素B（AmB）治疗利什曼病疗效影响的文章。利什曼病是一种全球性的寄生虫热带病，主要治疗药物之一是AmB。然而，由于其毒性和不溶性问题，AmB的临床应用受到限制。使用纳米颗粒，特别是壳聚糖纳米载体，似乎是克服这些问题的一种有前途的方法。因此，在不同研究中，已将不同剂量的AmB负载于壳聚糖纳米颗粒中，这些研究结果表明，通过提高药物负载效率和降低毒性，纳米制剂抑制和杀死寄生虫的效力得以提高。在这方面，2018年进行的一项研究结果表明，药物负载量较高的壳聚糖纳米颗粒是抑制和杀死寄生虫最有效的制剂。因此，壳聚糖纳米载体未来可被视为抑制和杀死利什曼原虫且不产生副作用的合适候选物。
